Benralizumab is a humanized monoclonal antibody which binds to the α subunit of the
interleukin-5 (IL-5) receptor and to the FcγRIIIa receptor expressed by natural killer cells …

Background Eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP) are
proteins released by activated eosinophils whose role in adult asthma remains unclear …

Background Anti-IL-5 antibodies represent an established therapy for severe eosinophilic
asthma (SEA), but some patients show inadequate response. The objective of this study was …

Aging is associated with a dysregulation of the immune system, leading to a general pro-
inflammatory state of the organism, a process that has been named inflamm-aging …

Background: Patients with mild asthma are believed to represent the majority of patients with
asthma. Disease-associated risks such as exacerbations, lung function decline, and death …

Background Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic
asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We …

Mepolizumab is a humanized monoclonal antibody which targets interleukin-5 (IL-5) and is
nowadays available in many countries for add-on biological therapy of severe eosinophilic …

Objective Severe asthma can be classified into phenotypes and endotypes, which may
inform clinicians about inflammatory pathways leading to disease and ultimately guide …

Introduction: Bronchial asthma (BA) is a chronic airways inflammatory disease. Based on the
biological mechanisms that underline the disease, asthma has been classified as type 2 or …

Despite treatment with standard-of-care medications, including currently available biologic
therapies, many patients with severe asthma have uncontrolled disease, which is associated …